These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 9836122)

  • 1. [Clinical evaluation of cefozopran for infections associated with hematological malignancies].
    Sasai Y; Iwai T; Tamura A; Nakazawa N; Ueda Y; Kaneko H; Horiike S; Yokota S; Taniwaki M; Kashima K; Misawa S; Tsuda S; Ohgawara Y
    Jpn J Antibiot; 1998 Aug; 51(8):501-8. PubMed ID: 9836122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy and safety of cefozopran (CZOP) monotherapy and combination therapy with CZOP and amikacin (AMK) for infections accompanying hematological diseases].
    Urabe A; Fujita A; Aoki K; Koike M; Kitamura K; Ohbayashi Y; Oshimi K; Wakabayashi Y; Kuraishi Y; Kurihara I; Togawa A; Hoshino S; Ozawa K; Hotta T; Higashihara M; Nagoshi H; Hirai H; Omine M; Asano S; Nishimura M; Suzuki K; Bessho M; Mizoguchi H; Furusawa S; Nonaka Y; Takaku F
    Jpn J Antibiot; 2000 Feb; 53(2):61-74. PubMed ID: 10786314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical evaluation of panipenem/betamipron as a second line chemotherapy in severe infections associated with hematological disorders].
    Nakazawa N; Okamoto T; Kobayashi M; Iwai T; Sasai Y; Tamura A; Horiike S; Yokota S; Taniwaki M; Kashima K; Misawa S; Tuda S; Ohkawara Y
    Jpn J Antibiot; 1998 Aug; 51(8):509-20. PubMed ID: 9836123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical effects of combination therapy with cefozopran and tobramycin for severe infections in patients with hematologic diseases].
    Toyama K; Yaguchi M; Uchida Y; Suzuki K; Sawanobori M; Ikeda Y; Matsuoka S; Wakasugi K; Furuya T; Oshimi K; Kawamata N; Kikuchi M; Murakami H; Tsuruoka N; Tomoyasu S; Kawaguchi M; Hirosawa S; Yamamoto K; Shirota T; Harada Y; Dan K; Yamada T; Kawano K; Onozawa Y; Takeuchi J
    Jpn J Antibiot; 1999 Feb; 52(2):153-61. PubMed ID: 10221180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Optimum dose study of cefozopran in the pediatric field].
    Fujii R; Sunakawa K; Sato Y; Yokota T; Yoshimura K; Kondoh Y; Kawaoi Y; Terashima I; Meguro H; Niinou K; Toyonaga Y; Ishihara T; Iwai N; Nakamura H; Kuno K; Miyajima Y; Sakurai M; Itoh M; Kawasaki H; Suga S; Kamiya H; Fujiwara T; Inui T; Taniguchi K; Nakayama M
    Jpn J Antibiot; 1996 Jul; 49(7):663-77. PubMed ID: 8828069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical evaluation of cefozopran as treatment for febrile neutropenia].
    Saito T; Hara M; Shinagawa K; Nawa Y; Nakase K; Takeuchi M; Miyata A; Fukuda S; Sunami K; Imajoh K; Yano T; Kojima K; Teshima T; Fujii N; Ishimaru F; Ikeda K; Harada M; Tanimoto M
    Gan To Kagaku Ryoho; 2004 Jan; 31(1):61-5. PubMed ID: 14750323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical effects of combination therapy with cefozopran and amikacin for infections in patients with hematological disorders].
    Fukuda M; Endo K; Takinami S; Kawai N; Tominaga K; Maesaki S; Bessho M; Yamazaki T
    Jpn J Antibiot; 2001 Feb; 54(2):88-94. PubMed ID: 11338682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacokinetic and clinical studies with cefozopran in the pediatric field. Pediatric Study Group of Cefozopran].
    Fujii R; Abe T; Tajima T; Terashima I; Meguro H; Nakazawa S; Sato H; Niinou K; Sunakawa K; Yokota T
    Jpn J Antibiot; 1994 Jan; 47(1):102-23. PubMed ID: 8114268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical evaluation of ceftazidime monotherapy for infections complicated with hematological disorders].
    Kuzuyama Y; Tsuda S; Seriu T; Nakai H; Murakami T; Takashima T; Takahashi Y; Tanaka S; Nakagawa H; Nishigaki H
    Jpn J Antibiot; 1992 May; 45(5):523-9. PubMed ID: 1512938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapeutic effects of a combination treatment with cefmetazole and netilmicin against infections complicated with hematological disorders].
    Yamane T; Nakao Y; Yasui Y; Ota K; Ohira H; Inoue T; Furukawa Y; Hiyoshi M; Sasaki A; Kishida T
    Jpn J Antibiot; 1990 Nov; 43(11):1843-9. PubMed ID: 2287053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical investigation of the therapeutic effects of cefmenoxime in the treatment of infections complicated by hematological diseases].
    Kozuru M; Kurata T; Uike N; Niho Y; Shibuya T; Otsuka T; Yamano Y; Hirota Y; Nishimura J; Katsuno M
    Jpn J Antibiot; 1986 Mar; 39(3):701-12. PubMed ID: 3488422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of severe infections in hematologic malignancies with piperacillin sodium].
    Kubota Y; Ohnishi H; Murata M; Nagai M; Ikeda K; Tanaka T; Irino S
    Jpn J Antibiot; 1991 Mar; 44(3):317-23. PubMed ID: 1880913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical evaluation of a combination therapy using cefmenoxime and cefsulodin on infections complicated by hematological disorders. Tohkai Research Group on Infections in Hematopoietic Disorders].
    Minami N; Uno N; Shirakawa S; Ohno R; Okumura M; Yamamoto M; Mitomo Y; Hirano M; Shimizu S; Yamada K
    Jpn J Antibiot; 1986 Mar; 39(3):713-20. PubMed ID: 3488423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical evaluation of a new parenteral cephem, cefozopran, in children].
    Taniuchi S; Higashino H; Takaya J; Ishizaki Y; Kino M; Man W; Kobayashi Y
    Jpn J Antibiot; 1994 Nov; 47(11):1553-8. PubMed ID: 7853685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapeutic effects of micronomicin against severe infections in patients with hematopoietic disorders. Hanshin Infection Study Group].
    Hasegawa H; Horiuchi A; Nagai K; Kanamaru A; Masaoka T; Shibata H; Kitani T; Taniguchi N; Yasunaga K; Okamoto Y
    Jpn J Antibiot; 1985 Aug; 38(8):2129-38. PubMed ID: 3908733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical evaluation of sulbactam/cefoperazone for severe infections associated with hematological disorders].
    Kitamura K; Takaku F; Miyazaki T; Miura ; Mizoguchi H; Saito H; Masaoka T; Kimura I; Niho Y
    Jpn J Antibiot; 1991 Sep; 44(9):979-86. PubMed ID: 1960859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effects of cefoxitin in the treatment of severe infections in patients with hematopoietic disorders].
    Hasegawa H; Horiuchi A; Nagai K; Kanamaru A; Masaoka T; Shibata H; Kitani T; Tsubakio T; Kawagoe H; Shinohara Y; Nasu T
    Jpn J Antibiot; 1982 May; 35(5):1212-22. PubMed ID: 6752459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A combined consecutive therapy with fosfomycin and sulbactam/cefoperazone for bacterial infections associated with hematological diseases].
    Misawa S; Tsuda S; Taniwaki M; Horiike S; Ariyama Y; Hirakawa K; Ueda Y; Kaneko H; Nakao M; Kashima K
    Jpn J Antibiot; 1995 Apr; 48(4):514-21. PubMed ID: 7540219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacokinetic, bacteriological and clinical studies on cefozopran in neonates and premature infants. A study of cefozopran in the perinatal co-research group].
    Fujii R; Okuno A; Fujita K; Kakuya F; Maruyama S; Sakata H; Inyaku F; Abe T; Hashira S; Nakazato Y; Sugiura M; Tajima T; Nagai S; Funamoto N; Sugimori S; Nishimura S; Yoshimura K; Kondoh Y; Kawaoi Y; Terashima I; Meguro H; Takeuchi Y; Kantake M; Sunakawa K; Yagisawa M
    Jpn J Antibiot; 1996 Jul; 49(7):678-702. PubMed ID: 8828070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical evaluation of cefozopran in the pediatric field].
    Meguro H; Fujii R; Terashima I
    Jpn J Antibiot; 1994 Nov; 47(11):1464-72. PubMed ID: 7853677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.